PEN News and Press, Penumbra Inc. From 04/07/23

2023-04-07 06:35:01 ET Summary Penumbra has demonstrated its capacity to unlock long-term shareholder value. After a lumpy performance in FY'22, shares have since re-rated more than 100% higher off lows. Findings from the deep dive presented here illustrate PEN's capacity to g...

Penumbra, Inc. Schedules First Quarter 2023 Earnings Release and Conference Call for May 2, 2023 PR Newswire ALAMEDA, Calif. , April 4, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial result...

Penumbra and Veterans Health Administration to Expand Access to Rehabilitative Care using Virtual Reality PR Newswire Penumbra enters a three-year collaboration with VHA Office of Healthcare Innovation and Learning to test, co-develop and scale virtual reality solutions Co...

Penumbra, Inc. (PEN) Q4 2022 Earnings Conference Call February 23, 2023 04:30 PM ET Company Participants Jee Hamlyn-Harris - Investor Relations Adam Elsesser - Chairman & Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice...

Penumbra press release ( NYSE: PEN ): Q4 Non-GAAP EPS of $0.16 beats by $0.01 . Revenue of $221.22M (+8.4% Y/Y) beats by $4.19M . For further details see: Penumbra Non-GAAP EPS of $0.16 beats by $0.01, revenue of $221.22M beats by $4.19M

Penumbra, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results PR Newswire ALAMEDA, Calif. , Feb. 23, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial resu...

Penumbra, Inc. to Present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference Penumbra, Inc. to Present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference PR Newswire ALAMEDA, Calif. , Feb. 16, 2023 /PRNewswire/ -- P...

Summary Stryker posted impressive top-line growth in Q4, driven by mid-teens growth in the MedSurg & Neuro operations. Margins remain a drag as Stryker has struggled to offset higher input costs. I see upside potential in FY'23 revenue, with Stryker launching several significant...

Summary After years of struggling to make real progress in its core atherectomy businesses, CSII is selling out to Abbott for $20/share in cash. Abbott is acquiring an established but likely slower-growing atherectomy business that has been disrupted by ShockWave's entry into the periph...

Penumbra, Inc. Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 23, 2023 PR Newswire ALAMEDA, Calif. , Jan. 26, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to dis...